bezafibrate (Discontinued)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Investigational in the United States

Barth Syndrome (Orphan)

Orphan designation for Barth syndrome

Orphan sponsor

  • Barth Sydrome Foundation, Inc.; P. O. Box 618; Larchmont, NY 10538

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and bezafibrate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            1-10%

            Allergic reaction

            Anorexia

            Anemia

            Constipation

            CPK increased

            Creatinine increased

            Diarrhea

            Dizziness

            Dyspepsia

            Eczema

            Flatulence

            Gastritis

            Insomnia

            Migraine

            Nausea

            Pain

            Pruritus

            Rash

            Transaminases increased

            <1%

            Cholelithiasis

            Myopathy

            Rhabdomyolysis

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to bezafibrate, fibrates

            Primary biliary cirrhosis

            Pre-existing gallbladder disease

            Concurrent use of MAO inhibitors

            Pregnancy or breast-feeding

            Cautions

            History of jaundice or hepatic disorder

            Concurrent use of HMG-CoA reductase inhibitors

            Hepatic/renal impairment

            Hypoalbuminemia or nephrotic syndrome

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: Not available. Not recommended.

            Lactation: excretion in milk unknown/not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Increases VLDL catabolism by increasing lipoprotein and hepatic triglyceride lipase activities

            Decreases triglyceride biosynthesis by inhibiting acetyl-CoA carboxylase

            Decreases cholesterol biosynthesis by inhibiting 3-hydroxyl-3-methyglutaryl coenzyme A reductase

            Absorption

            Bioavailability: Almost complete (immediate-release); 70% (sustained-release)

            Peak plasma time: 1-2 hr (immediate-release); 3-4 hr (sustained-release)

            Distribution

            Vd: 17 L

            Protein bound: 94-96%

            Elimination

            Half-life: 1-2 hr

            Excretion: 95% urine; 3% feces

            Previous
            Next:

            Images

            Previous
            Next: